CHMMF.US Chimeric Therapeutics Limited

Healthcare Biotechnology USA Stocks
0.1000 USD
Close of Nov 13, 2026
0.1000 0.1000
Market cap
USD 14.7M
P/E
-
P/B
0.54x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CHMMF.US undervalued?

Graham number

The Graham number of Chimeric Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Chimeric Therapeutics Limited fundamental analysis

No fundamental analysis for Chimeric Therapeutics Limited yet.

Chimeric Therapeutics Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Chimeric Therapeutics Limited

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MM…

Full company profile